790 Township Line Road
Yardley, PA 19067
342 42nd Street South
Fargo, ND 58103
About Clinigen US
As the world’s largest pharmaceutical market, the US continues to play a pivotal role in Clinigen’s growth story. Clinigen’s US location offers fast and convenient access to decision-makers in our client companies and in the Clinigen business, as well as being close to world famous research and academic institutions, key opinion leaders and industry conferences.
The Yardley team brings decades of knowledge and experience to the early access and clinical trial services space, and with the US being the first launch market for many products the team there plays a vital role in ensuring that patients in need around the world can get access to the medicines they need, whether through a clinical trial, early access or a commercially available product.
Our US team has extensive first-hand experience of the unique local regulatory and commercial environments and works with clients to maximise access to medicine through all stages of the product lifecycle. The office there is our gateway to North America and, increasingly, our springboard to expansion in Central and South America.
To offer a truly valuable service to its pharmaceutical and biotech clients' the nascent Clinigen needed to expand beyond the UK, and the first place we did so was in the US.
From first establishing a permanent presence in 2008 until today, with more than 30 full-time employees based in the US, the Yardley office is a key hub for both Clinical Trial and Unlicensed Medicine Services.
Located close to the global headquarters of many pharmaceutical and biotech firms' the Yardley office is home to numerous Project Managers, Business Developers and Program Managers, and more recently has added colleagues from our Clinigen Consulting Group and Medicines Access team. The convenient location means that the Yardley team is able to easily interact with healthcare professionals and pharmaceutical decision-makers in North and South America in person, over the phone and via email, ensuring we get the ‘right medicine, to the right patient, at the right time.’